Recent Updates
Recently added Catalysts
XERS Positive Sentiment

Copyright 2021-2025 Xeris Pharmaceuticals, Inc. All rights reserved. Welcome and Agenda Allison Wey SVP, Investor Relations and Corporate Communications 2 Copyright 2021-2025 Xeris Pharmaceuticals, Inc. All rights reserv

Key Takeaway: Xeris Pharmaceuticals hosted an Investor and Analyst Day focusing on Cushing's Syndrome and cortisol regulation. Key presentations included understanding the clinical complications associated with excess cortisol and the role of guidelines in testing and treatment. The event emphasized the importance of normalizing cortisol levels and addressing related comorbidities to optimize patient outcomes. Continued research and innovation were highlighted as critical to managing this condition effectively.
Price reaction · baseline $5.05 (2025-06-02 close) · hit after-hours · clean, no other XERS news in the window
day 0 close
-7.9%
day 1 · peak
-12.3%
day 3
-9.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Emphasis on the importance of normalizing cortisol levels to improve patient outcomes.
  • Highlight on the need for continued education to address diagnosis gaps.
  • Recognition of chronic hypercortisolism leading to multiple comorbidities, indicating a comprehensive approach to treatment.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+113%
120-day peak, hindsight
Typical move
9.8%
average across 3 past catalysts
Lead asset
Glucagon
Phase 3 · Diabetes Mellitus, Type 1

Full Press Release Details

Investor and Analyst Day June 3, 2025 1 Exhibit 99.1
20 Evolving Understanding of Cortisol, Cortisol Regulation, and Cushing's Syndrome Eliza B. Geer, MD
21 Understanding Cushing's Syndrome Cortisol excess due to a tumor producing ACTH or cortisol CORTISOL Adrenal steroid hormone Production & secretion regulated by HPA Axis Homeostasis: mediates circadian rhythm & stress response Metabolism: converts protein to glucose Immune system: reduces inflammation Exposure to excess cortisol over time causes multiple adverse clinical consequences HPA axis: hypothalamic-pituitary-adrenal axis; CRH: Corticotropin-releasing hormone; ACTH: Adrenocorticotropic hormone; DHEA: Dehydroepiandrosterone Thau L et al. Physiology, Cortisol (https://www.ncbi.nlm.nih.gov/books/NBK538239/). 2023 Aug 28. In: Stat Pearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan. Accessed 5/5/2025.
22 Unique Presentations of Cushing's Syndrome ADRENAL CUSHING'S SYNDROME 13-YEAR DIAGNOSTIC JOURNEY ADRENAL CUSHING'S SYNDROME 2-YEAR DIAGNOSTIC JOURNEY; FOLLOWING IDENTIFICATION OF TUMORS ON KIDNEY SCAN Actual Patient Actual Patient
23 Clinical Complications Cushing's Syndrome Reproductive/Sexual Nervous Endocrine Cardiovascular Musculoskeletal Neuropsychiatric disorders Arterial atherosclerosis and vascular disease Diabetes Osteoporosis (femoral neck) Myopathy Cardiac disease Impaired reproductive/sexual function Dermatologic manifestations Visceral obesity Infections Osteoporosis (spine) and vertebral fractures Adapted from: Pivonello R, et al. Lancet Diabetes Endocrinol 2016;4(7):611-629.
24 Role of Guidelines in Advancing Clinical Considerations in Testing & Treatment 2008 Endocrine Society Guidelines1 Testing: Widespread testing not necessary beyond: Multiple and progressive features predictive of Cushing's syndrome Adrenal incidentalomas compatible with adenoma 2015 Endocrine Society Guidelines2 Treatment Goals: Normalize cortisol levels Eliminate signs and symptoms of Cushing's Syndrome Treat comorbidities associated with hypercortisolism 2021 Pituitary Society Consensus3 Testing: Clinical judgement and suspicion for Cushing's syndrome very important Medical therapy goals: Individualized therapy based on clinical & severity of hypercortisolism Normalize cortisol levels 1. Nieman LK et al. J Clin Endocrinol Metab. May 2008, 93(5):1526-1540 2. Nieman LK, et al. J Clin Endocrinol Metab. 2015;100(8):2807-2831; 3. Fleseriu M et al. The Lancet Diabetes & Endocrinology, Volume 9, Issue 12, 847 - 875.
25 Clinical Approaches to Normalizing Cortisol Levels Clinical Pathway Following Diagnosis Confirmation Surgery Radiation Medical Therapy 1. Hinojosa-Amaya JM, et al. Drugs. 2019;79(9):935-956.
26 Clinical Approaches to Normalizing Cortisol Levels 1. Hinojosa-Amaya JM, et al. Drugs. 2019;79(9):935-956. 2. Fleseriu M, et al. Expert Rev Endocrinol Metab. 2021;16(4):159-174.
27 Goal: Optimize Patient Outcomes & Improve Quality of Life Continued education needed to address clinical diagnosis gaps Priority is to normalize cortisol levels and address comorbidities Chronic hypercortisolism can lead to multisystem comorbidities Continued Efforts in Advancing Research, Medical Innovations, and Guidelines are Needed to Address Cushing's Syndrome & Holistic Burden of Illness Page-Wilson G, et al. Endocrinol Diab Metab. 2024; 7:e464. doi:10.1002/edm2.464

Frequently Asked Questions

What causes Cushing's syndrome?

Cushing's syndrome results from excess cortisol, often due to a tumor producing ACTH or cortisol.

What are the complications of Cushing's syndrome?

Cushing's syndrome can lead to reproductive, cardiovascular, and neuropsychiatric disorders, among others.

How is Cushing's syndrome diagnosed?

Diagnosis involves identifying multiple and progressive symptoms, often using clinical judgment.

What are treatment goals for Cushing's syndrome?

Goals include normalizing cortisol levels and alleviating symptoms of Cushing's syndrome.

What steps are taken to normalize cortisol levels?

Strategies include surgery, radiation, and medical therapy following diagnosis confirmation.

Last updated: Jun 3, 2025